11 results
8-K
EX-99.1
GLTO
Galecto Inc
27 Jan 22
Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
8:31am
related thrombosis, and the processes of acute and chronic fibrosis. These novel findings enhance our conviction for the potentially wide medical
8-K
EX-99.1
GLTO
Galecto Inc
5 Jan 22
Regulation FD Disclosure
4:02pm
2021 Phase 1 SAD/MAD study completed Chronic toxicology studies completed Robust efficacy in lung, liver and kidney fibrosis models Expected topline
10-K
2020 FY
GLTO
Galecto Inc
29 Mar 21
Annual report
6:03am
to 20 percent of cancers linked to chronic inflammation-linked fibrosis. It has been estimated that fibrosis contributes to up to 45 percent of all deaths … for assessing the prognosis of patients diagnosed with chronic heart failure.
Figure 3. Multiple roles of galectin-3 in fibrosis
Interestingly, studies have
8-K
EX-99.1
52u3k8ea
5 Jan 21
Results of Operations and Financial Condition
4:31pm
10-Q
kp15bdo8vqm i17yu0ac
11 Dec 20
Quarterly report
7:30am
424B4
d2k taknj8znlr84cx
30 Oct 20
Prospectus supplement with pricing info
4:31pm
S-1/A
omc2e u290a8eht9
22 Oct 20
IPO registration (amended)
6:13am
S-1
cv3ey5ezhwaig5rgc
7 Oct 20
IPO registration
5:01pm
DRS
1cvd6bcxnq57bsg9432
2 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next